Tumor-related methylated cell-free DNA and circulating tumor cells in melanoma

Frontiers in Molecular Biosciences

Volumn 2, Issue JAN, 2016, Pages

  Salvianti, Francesca ^a   Orlando, Claudio ^a   Massi, Daniela ^b   De Giorgi, Vincenzo ^b   Grazzini, Marta ^b   Pazzagli, Mario ^a   Pinzani, Pamela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cell free DNA; Circulating tumor cells; Epigenetic marker; Melanoma; Tumor marker

Indexed keywords

EID: 85016144570     PISSN: None     EISSN: 2296889X     Source Type: Journal    
DOI: 10.3389/fmolb.2015.00076     Document Type: Article

References (45)

1. Agostini, M., Enzo, M. V., Bedin, C., Belardinelli, V., Goldin, E., Del Bianco, P., et al. (2012). Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark. 11, 89-98. doi: 10.3233/CBM-2012-0263
2. Alix-Panabières, C., Schwarzenbach, H., and Pantel, K. (2012). Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 63, 199-215. doi: 10.1146/annurev-med-062310-094219
3. Balgkouranidou, I., Matthaios, D., Karayiannakis, A., Bolanaki, H., Michailidis, P., Xenidis, N., et al. (2015). Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutat. Res. 778, 46-51. doi: 10.1016/j.mrfmmm.2015.05.002
4. Begum, S., Brait, M., Dasgupta, S., Ostrow, K. L., Zahurak, M., Carvalho, A. L., et al. (2011). An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17, 4494-4503. doi: 10.1158/1078-0432.CCR-10-3436
5. Bidard, F. C., Madic, J., Mariani, P., Piperno-Neumann, S., Rampanou, A., Servois, V., et al. (2014). Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int. J. Cancer 134, 1207-1213. doi: 10.1002/ijc.28436
6. Board, R. E., Knight, L., Greystoke, A., Blackhall, F. H., Hughes, A., Dive, C., et al. (2008). DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark. Insights 2, 307-319
7. Bondurant, A. E., Huang, Z., Whitaker, R. S., Simel, L. R., Berchuck, A., and Murphy, S. K. (2011). Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol. Oncol. 123, 581-587. doi: 10.1016/j.ygyno.2011.08.029
8. Chan, K. C., Ding, C., Gerovassili, A., Yeung, S. W., Chiu, R. W., Leung, T. N., et al. (2006). Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem. 52, 2211-2218. doi: 10.1373/clinchem.2006.074997
9. Chimonidou, M., Strati, A., Malamos, N., Georgoulias, V., and Lianidou, E. S. (2013). SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin. Chem. 59, 270-279. doi: 10.1373/clinchem.2012.191551
10. De Giorgi, V., Pinzani, P., Salvianti, F., Panelos, J., Paglierani, M., Janowska, A., et al. (2010). Application of a filtration-and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J. Invest. Dermatol. 130, 2440-2447. doi: 10.1038/jid.2010.141
11. de Martino, M., Klatte, T., Haitel, A., and Marberger, M. (2012). Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer 118, 82-90. doi: 10.1002/cncr.26254
12. Diaz, L. A. Jr., and Bardelli, A. (2014). Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579-586. doi: 10.1200/JCO.2012.45.2011
13. Donninger, H., Clark, J., Rinaldo, F., Nelson, N., Barnoud, T., Schmidt, M. L., et al. (2015). The RASSF1A tumor suppressor regulates XPA-mediated DNA repair. Mol. Cell. Biol. 35, 277-287. doi: 10.1128/MCB.00202-14
14. Donninger, H., Vos, M. D., and Clark, G. J. (2007). The RASSF1A tumor suppressor. J. Cell. Sci. 120, 3163-3172. doi: 10.1242/jcs.010389
15. Ellinger, J., Albers, P., Perabo, F. G., Müller, S. C., von Ruecker, A., and Bastian, P. J. (2009). CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J. Urol. 182, 324-329. doi: 10.1016/j.juro.2009.02.106
16. Fleischhacker, M., and Schmidt, B. (2007). Circulating nucleic acids (CNAs) and cancer-a survey. Biochim. Biophys. Acta 1775, 181-232. doi: 10.1016/j.bbcan.2006.10.001
17. Freidin, M. B., Freydina, D. V., Leung, M., Montero Fernandez, A., Nicholson, A. G., and Lim, E. (2015). Circulating tumor DNA outperforms circulating tumor cells for KRAS Mutation detection in thoracic malignancies. Clin. Chem. 61, 1299-1304. doi: 10.1373/clinchem.2015.242453
18. Hauser, S., Kogej, M., Fechner, G., VON Pezold, J., Vorreuther, R., Lümmen, G., et al. (2013). Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res. 33, 779-784
19. Hodgson, D. R., Wellings, R., Orr, M. C., McCormack, R., Malone, M., Board, R. E., et al. (2010). Circulating tumour-derived predictive biomarkers in oncology. Drug Discov. Today 15, 98-101. doi: 10.1016/j.drudis.2009.12.006
20. Hoon, D. S., Bostick, P., Kuo, C., Okamoto, T., Wang, H. J., Elashoff, R., et al. (2000). Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60, 2253-2257
21. Hoon, D. S., Spugnardi, M., Kuo, C., Huang, S. K., Morton, D. L., and Taback, B. (2004). Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23, 4014-4022. doi: 10.1038/sj.onc.1207505
22. Jung, K., Fleischhacker, M., and Rabien, A. (2010). Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin. Chim. Acta 411, 1611-1624. doi: 10.1016/j.cca.2010.07.032
23. Khoja, L., Lorigan, P., Dive, C., Keilholz, U., and Fusi, A. (2015). Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. Ann. Oncol. 26, 33-39. doi: 10.1093/annonc/mdu207
24. Koyanagi, K., Mori, T., O'Day, S. J., Martinez, S. R., Wang, H. J., and Hoon, D. S. (2006). Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 66, 6111-6117. doi: 10.1158/0008-5472.CAN-05-4198
25. Liggett, T. E., Melnikov, A., Yi, Q., Replogle, C., Hu, W., Rotmensch, J., et al. (2011). Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol. Oncol. 120, 113-120. doi: 10.1016/j.ygyno.2010.09.019
26. Madic, J., Kiialainen, A., Bidard, F. C., Birzele, F., Ramey, G., Leroy, Q., et al. (2015). Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int. J. Cancer 136, 2158-2165. doi: 10.1002/ijc.29265
27. Marini, A., Mirmohammadsadegh, A., Nambiar, S., Gustrau, A., Ruzicka, T., and Hengge, U. R. (2006). Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J. Invest. Dermatol. 126, 422-431. doi: 10.1038/sj.jid.5700073
28. Matuschek, C., Bölke, E., Lammering, G., Gerber, P. A., Peiper, M., Budach, W., et al. (2010). Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur. J. Med Res. 15, 277-286. doi: 10.1186/2047-783X-15-7-277
29. Mori, T., O'Day, S. J., Umetani, N., Martinez, S. R., Kitago, M., Koyanagi, K., et al. (2005). Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J. Clin. Oncol. 23, 9351-9358. doi: 10.1200/JCO.2005.02.9876
30. Papadopoulou, E., Davilas, E., Sotiriou, V., Georgakopoulos, E., Georgakopoulou, S., Koliopanos, A., et al. (2006). Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. N. Y. Acad. Sci. 1075, 235-243. doi: 10.1196/annals.1368.032
31. Pinzani, P., Mazzini, C., Salvianti, F., Massi, D., Grifoni, R., Paoletti, C., et al. (2010b). Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression. Melanoma Res. 20, 303-310. doi: 10.1097/CMR.0b013e32833906e3
32. Pinzani, P., Salvianti, F., Cascella, R., Massi, D., De Giorgi, V., Pazzagli, M., et al. (2010a). Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. Clin. Chim. Acta 411, 1319-1324. doi: 10.1016/j.cca.2010.05.024
33. Ponomaryova, A. A., Rykova, E. Y., Cherdyntseva, N. V., Skvortsova, T. E., Dobrodeev, A. Y., Zav'yalov, A. A., et al. (2013). Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer 81, 397-403. doi: 10.1016/j.lungcan.2013.05.016
34. Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G., et al. (2012). Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18, 2391-2401. doi: 10.1158/1078-0432.CCR-11-3148
35. Rodic, S., Mihalcioiu, C., and Saleh, R. R. (2014). Detection methods of circulating tumor cells in cutaneous melanoma: a systematic review. Crit. Rev. Oncol. Hematol. 91, 74-92. doi: 10.1016/j.critrevonc.2014.01.007
36. Salvianti, F., Pinzani, P., Verderio, P., Ciniselli, C. M., Massi, D., De Giorgi, V., et al. (2012). Multiparametric analysis of cell-free DNA in melanoma patients. PLoS ONE 7:e49843. doi: 10.1371/journal.pone.0049843
37. Schwarzenbach, H., Alix-Panabières, C., Müller, I., Letang, N., Vendrell, J. P., Rebillard, X., et al. (2009). Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res. 15, 1032-1038. doi: 10.1158/1078-0432.CCR-08-1910
38. Schwarzenbach, H., Hoon, D. S., and Pantel, K. (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426-437. doi: 10.1038/nrc3066
39. Skvortsova, T. E., Rykova, E. Y., Tamkovich, S. N., Bryzgunova, O. E., Starikov, A. V., Kuznetsova, N. P., et al. (2006). Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer 94, 1492-1495. doi: 10.1038/sj.bjc.6603117
40. Spugnardi, M., Tommasi, S., Dammann, R., Pfeifer, G. P., and Hoon, D. S. (2003). Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 63, 1639-1643
41. Tanemura, A., Terando, A. M., Sim, M. S., van Hoesel, A. Q., de Maat, M. F., Morton, D. L., et al. (2009). CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res. 15, 1801-1807. doi: 10.1158/1078-0432.CCR-08-1361
42. Van der Auwera, I., Elst, H. J., Van Laere, S. J., Maes, H., Huget, P., Van Dam, P., et al. (2009). The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br. J. Cancer 100, 1277-1286. doi: 10.1038/sj.bjc.6605013
43. Warton, K., and Samimi, G. (2015). Methylation of cell-free circulating DNA in the diagnosis of cancer. Front. Mol. Biosci. 2:13. doi: 10.3389/fmolb.2015.00013
44. Wong, T. S., Kwong, D. L., Sham, J. S., Wei, W. I., Kwong, Y. L., and Yuen, A. P. (2004). Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin. Cancer Res. 10, 2401-2406. doi: 10.1158/1078-0432.CCR-03-0139
45. Zhang, Q., Hu, G., Yang, Q., Dong, R., Xie, X., Ma, D., et al. (2013). A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol. Oncol. 130, 132-139. doi: 10.1016/j.ygyno.2013.04.048